Carcinotech Secures £1.6 million funding to expand internationally

Carcinotech has secured £1.6 million in funding to accelerate commercialisation plans and expand internationally.

The medical technology start-up manufactures 3D printed tumours developed from cancer stem cells, primary cells and established cell lines.

Tricaptial led the investment round, succeeding initial seed round leader Gabriel Investments, alongside Eos Advisory, SIS Ventures, Alba Equity and Scottish Enterprise.

Read the full article here.

Related Posts

About Us

Carcinotech is a MedTech company with expertise in manufacturing 3D printed living tumours using patient-derived biopsies, primary cells, immune cells and cancer stem cells.

Let’s Socialize

Popular Post